General news

  • February 29th, 2024

From Images to Impact: Radiomics' Solutions to Challenges in Immunotherapy

Up to 30% of patients may experience hyper progression following immunotherapy. Identifying patients who will actually benefit from immunotherapy is intrinsic to achieving optimal outcomes. Radiomics can offer a solution to this problem by analysing the phenotypical changes in lesions and organs that may occur following the initiation of a treatment.

  • September 5th, 2023

Pilot project at the Jewish General Hospital aims to accelerate access to new and highly effective treatments for cancer patients

Pilot project at the Jewish General Hospital aims to accelerate access to new and highly effective treatments for cancer patients

  • April 7th, 2023

Belgian biotech companies DeuterOncology and Radiomics combine their expertise to improve cancer therapy

DeuterOncology joins forces with Radiomics to develop a clinical tool to predict patient response to treatment.

  • November 23rd, 2022

Radiomics' Event Package for IO Xchange

Here is the online version of our event package. Sign up to get access.

  • November 14th, 2022

Early Detection with Imaging

Paving the way for better diagnosis, treatment and care in pulmonary fibrosis

  • November 11th, 2022

Radiomics' Event Information Package for SITC

Here is our digital event package. Sign up to get access.

  • October 14th, 2022

Radiomics’ Remarkable Relocation 

After 4 years, Radiomics is moving to LégiaPark 

  • October 14th, 2022

Radiomics déménage au LégiaPark

Après 4 ans Radiomics déménage au LégiaPark

  • October 14th, 2022

Radiomics verhuist

Na 4 jaar verhuist Radiomics naar LégiaPark

  • September 8th, 2022

Radiomics' Event Package for ESMO

Here is the online version of our information package. Sign up to get access.

  • July 15th, 2022

New Beginnings - Radiomics 1st Newsletter

Radiomics is pleased to share the 1st edition of its newsletter series. Sign up to stay up to date with the latest news from Radiomics!

  • May 24th, 2022

Radiomics' Event Information Package for ASCO

Here is the online version of our information package. Sign up to get access.

  • April 28th, 2022

Radiomics Sustainability Policy

Radiomics is pleased to share its sustainability policy, the measures in place and the actions we plan to take to make a positive impact on the environment around us.

  • April 21st, 2022

The clinical needs and regulatory requirements of an imaging-based companion diagnostic

The fourth part in the series of articles about imaging-based companion diagnostics will focus on the necessary regulations and considerations and is available to read here.

  • March 22nd, 2022

Technical considerations for an imaging-based companion diagnostic

The third part in the series of articles about imaging-based companion diagnostics will focus on their integration into clinics and is available to read here.

  • March 15th, 2022

Radiomics is officially ISO 13485 certified

Radiomics is pleased to announce its Quality Management System has been certified to be fully compliant with EN ISO 13485:2016 Medical Devices – Quality Management Systems – Requirements for regulatory purposes) standard by the notified body IMQ.

  • February 16th, 2022

9 in 10 pivotal clinical trials in oncology fail: Radiomics can help to make the best use of research investments

A recent review showed that 9 out of 10 clinical trials fail to test the therapy as effective, this begs the question if all potential insights from early-stage testing are being captured and used to guide the success in late-stage research and clinical use?

  • December 13th, 2021

Developing an imaging-based companion diagnostic tool with Radiomics

The second part in the series of articles about imaging-based companion diagnostics will focus on their development and is available to read here.

  • December 1st, 2021

Radiomics joins the FNIH Biomarkers Consortium

Radiomics is proud to join the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC).

  • November 25th, 2021

Radiomics announces the strategic support of OncoDNA in its prospective clinical trial SALMON

The two Belgian companies will work towards a better understanding of non-small cell lung cancer biology and characterization of the tumors using of AI technology

  • November 17th, 2021

Radiomics secures €6 Million to fund new projects and initiatives

Radiomics announced that it has secured €6 Million in a pre-series B funding led by its main investors (Epimede and Noshaq) and backed by its original funders, its management team, some banks and non-dilutive financing from Walloon Regional Authorities in support of R&D Projects.

  • November 9th, 2021

Kazia Therapeutics and Radiomics collaborate in development of novel therapy

Radiomics, AI-powered imaging research organization, and Kazia Therapeutics, Australian oncology company developing innovative, high-impact drugs for cancer, announced that they have entered into a partnership to enhance imaging insights for the clinical development of EVT801.

  • November 4th, 2021

What is an Imaging-based Companion Diagnostics and why is it needed?

Radiomics has produced a series of articles aimed at providing a complete overview of imaging companion diagnostics and their development pathway. The first one has now been released and is available by dropping an email to [email protected]

  • August 24th, 2021

First distributed learning network machines for DRAGON installed

Radiomics installed in CHU Liege and University of Florence the first machines required for the connection to the distributed learning network in the framework of DRAGON. This project, funded by the European Commission’s Horizon 2020 program Innovative Medicine Initiative (IMI) aimed at using artificial intelligence (AI) and machine learning to develop decision support systems capable of delivering a more precise coronavirus diagnosis and more accurate predictions of patient outcomes.

  • May 19th, 2021

Visite de Mathieu Michel, Secrétaire d’Etat à la Digitalisation

La société Radiomics est heureuse et fière d’annoncer la visite, ce 19 mai 2021, de Monsieur Mathieu Michel, Secrétaire d’Etat fédéral belge à la Digitalisation, chargé de la Simplification administrative, de la Protection de la vie privée et de la Régie des Bâtiments.

  • May 3rd, 2021

Radiomics Opens its first North American office in Toronto, Ontario

Radiomics is pleased to announce the official opening of its first North American sales and support office with the support of the Walloon investment support agency AWEX. The new office, established in Toronto, Ontario will kick-start the company's partnerships in the area, better accommodating pharma companies and clinicians’ needs through North America-based team members.

  • April 20th, 2021

Radiomics CEO Wim Vos guest at Tekna Talks

Wim Vos CEO of Radiomics guest at Tekna Talks: Drug discovery – from airflow around a bobsleigh to airflow in the lungs.

  • March 22nd, 2021

TIGER Consortium awarded EU Commission grant of EUR 6.9 million

The TIGER consortium led by eTheRNA immunotherapies and including Radiomics, is awarded an EU Commission’s grant for an HPV 16+ vaccine clinical trial

  • March 2nd, 2021

DRAGON: la IA contro il COVID-19

L’Europa ha lanciato un nuovo progetto chiamato Dragon, per applicare l’intelligenza artificiale alla battaglia contro il COVID-19.

  • February 22nd, 2021

Artificial intelligence helps doctors address inner ear problems

A new method to map the inner ear using artificial intelligence (AI). That is what the Belgian start-up Radiomics has developed in close collaboration with doctors and scientists from Maastricht UMC +, Maastricht University, Antwerp University Hospital (UZA) and the University of Antwerp.

  • February 18th, 2021

AI tool for the segmentation of the inner ear on MRI

Radiomics together with UZAntwerpen and UMaastricht, has developed a novel tool for the automatic identification of the inner ear on MRI

  • January 26th, 2021

OncoRadiomics becomes Radiomics

With great enthusiasm and pride, the OncoRadiomics team today unveils the company's new brand identity: ‘Radiomics’.

  • January 26th, 2021

Radiomics un nouveau nom et des objectifs de croissance

OncoRadiomics, spin-off de l’Université de Maastricht installée à Liège et spécialisée dans le développement d’outils innovants de radiométrie, devient Radiomics afin que cette nouvelle identité corresponde davantage à ses projets de développement et ses objectifs de croissance.

  • January 4th, 2021

Carlos Meca joins Radiomics as CCO

Radiomics is glad to start the new year 2021 announcing and welcoming its new Chief Commercial Officer (CCO) Carlos Contreras Meca!

  • December 30th, 2020

Radiomic CT Signature for Detecting COVID-19

Radiomics developed a fully automated AI framework to extract radiomics features to classify COVID-19 infected patients from standard-of-care medical images (CT).

  • November 30th, 2020

ESTRO 2020

Presentation of our work on the prospective validation of a radiomics signature for chemoradiotherapy lung cancer patients

  • October 30th, 2020

The DRAGON project: fighting Coronavirus pandemics

The DRAGON project led by Radiomics in partnership with 18 high-tech SMEs, academic research institutes, biotech and pharma partners, affiliated patient-centred organisations and professional societies from Belgium, Italy, the Netherlands, Switzerland and the UK, has been selected for funding by the Innovative Medicines Initiative (IMI), with an evaluation score placing it in the 95% percentile.

  • October 1st, 2020

Mariaelena Occhipinti joins Radiomics as CMO

Radiomics is glad to welcome its new Chief Medical Officer, Mariaelena Occhipinti!